• Acromegaly
• GEP-NETs
• Espohageal Variceal Bleeding
• Additional Publications of Interest
• Clinical Trials

The abstract for each article can be viewed free of charge, or you can access the full article by visiting http://www.ncbi.nlm.nih.gov/PubMed/.
*Note: you may be required to purchase the full article from PubMed.

You must have PowerPoint^®* to view the slides. If you do not have PowerPoint, click here to download the application.

Links on this site lead to resources located on servers maintained by third parties over whom Novartis Pharma AG has no control. As such, Novartis Pharma AG makes no representation as to the accuracy or any other aspect of the information contained on such servers. Please note that some of the indications listed below are not approved for Sandostatin^® LAR^® and should be considered investigational. For approved indications please see your local product information.

Cozzi et al.
Primary treatment of acromegaly with octreotide LAR^®: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006 April;91(4):1397-403. Epub 2006 Jan 31

Colao et al.
First-line octreotide-LAR^® therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006 64: Online publication

Colao et al.
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006 91(1):85-92

Bevan JS
The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005 90:1856-1863

Astruc et al
Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles. J Clin Pharmacol 2005; 45:836-844

Melmed S.
Acromegaly Review Article. New England Journal of Medicine 2006, 355: 2558-73

Lancranjan I, Atkinson AB.
Results of a European multicentre study with Sandostatin^® LAR^® in acromegalic patients. Sandostatin^® LAR^® Group. Pituitary 1999; 1: 105-14.

Sheppard MC.
Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 2003; 58: 387-99.

Mercadante S, Casuccio A, Mangione S
Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 2007

Massacesi C, Galeazzi G
Sustained release octreotide may have a role in the treatment of malignant bowel obstruction. Palliat Med 2006

Rosenoff SH, Gabrail NY, Conklin R et al
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol 2006

Modlin IM, Latich I, Kidd M et al
Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006

Butturini G, Bettini R, Missiaglia E et al
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006

Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, Milione M, Cattaruzza MS, Falconi M, David V, Ziparo V, Pederzoli P, Bordi C, Delle Fave G
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006

Matulonis UA, Seiden MV, Roche M et al
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 2005

Arnold R
Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005

Arnold R, Rinke A, Klose KJ et al
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005

Oeberg K, Kvols L, Caplin M et al
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004

Ripamonti C, Mercadante S
How to use octreotide for malignant bowel obstruction. Support Oncol 2004

Corley D.A., Cello J.P., Adkisson W. et al
Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001

Besson I., Ingrand P., Person B. et al
Sclerotherapy with or without octreotide for acute variceal bleeding. New Engl.J.Med. 1995

Sanaka et al
Octreotide for palliative treatment of bleeding from unresectable gastric cancer. Hepatogastroenterology (2005 Jul-Aug)

Shah et al
Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage. J Ayub Med Coll Abbottabad (2005 Jan-Mar)

Astruc et al
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol (2005 Jul)